All stock lists
InMode Ltd. (NASDAQ:INMD)
IL · Delayed Price · Currency is USD
Healthcare · Medical - Devices
13.97-0.08 (-0.57%)
Insider Score
––Not scored
INMD Insider Score
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
INMD analyst forecast
Best analysts covering INMD
- Barclays15%success rate · 13 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
INMD analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Barclays | Overweight | — | — | Reiterated | 2026-05-07 |
| — | Baird | Neutral | — | — | Reiterated | 2026-05-07 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2025-12-17 |
| — | UBS | Neutral | — | — | Reiterated | 2025-11-06 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2025-10-10 |
| — | Needham | Hold | — | — | Reiterated | 2025-10-10 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-07-30 |
| — | Needham | Hold | — | — | Reiterated | 2025-07-30 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2025-07-11 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-04-30 |
| — | BTIG | Neutral | — | — | Downgraded | 2025-04-29 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2025-04-29 |
| — | UBS | Neutral | — | — | Reiterated | 2025-04-29 |
| — | Needham | Hold | — | — | Reiterated | 2025-04-28 |
| — | Needham | Hold | — | — | Reiterated | 2025-04-14 |
| — | Jefferies | Hold | — | — | Reiterated | 2025-04-14 |
| — | Needham | Hold | — | — | Reiterated | 2025-04-09 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-02-05 |
| — | Needham | Hold | — | — | Reiterated | 2025-02-04 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-01-09 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-10-14 |
| — | Jefferies | Hold | — | — | Downgraded | 2024-07-23 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-07-15 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2024-07-12 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-04-12 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-02-15 |
| — | UBS | Neutral | — | — | Reiterated | 2024-02-14 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-01-18 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-01-04 |
| — | Canaccord Genuity | Hold | — | — | Reiterated | 2023-12-07 |
| — | UBS | Neutral | — | — | Downgraded | 2023-11-03 |
| — | Canaccord Genuity | Hold | — | — | Downgraded | 2023-10-13 |
| — | Barclays | Overweight | — | — | Reiterated | 2023-08-01 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2023-07-28 |
| — | Baird | Outperform | — | — | Reiterated | 2023-07-28 |
| — | Barclays | Overweight | — | — | Reiterated | 2023-05-04 |
| — | Needham | Hold | — | — | Downgraded | 2023-02-17 |
| — | Barclays | Overweight | — | — | Reiterated | 2023-02-15 |
| — | Needham | Buy | — | — | Reiterated | 2022-07-29 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2022-06-30 |
| — | Needham | Buy | — | — | Reiterated | 2022-05-03 |
| — | Needham | Buy | — | — | Reiterated | 2022-02-11 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2021-10-27 |
| — | Barclays | Overweight | — | — | Reiterated | 2021-10-13 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2021-10-13 |
| — | Needham | Buy | — | — | Reiterated | 2021-10-12 |
| — | Needham | Buy | — | — | Reiterated | 2021-09-27 |
| — | Needham | Buy | — | — | Reiterated | 2021-07-29 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2021-07-29 |
| — | Barclays | Overweight | — | — | Reiterated | 2021-07-13 |
| — | Needham | Buy | — | — | Reiterated | 2021-07-12 |
| — | Baird | Outperform | — | — | Reiterated | 2021-05-06 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2021-05-06 |
| — | UBS | Buy | — | — | Reiterated | 2021-02-11 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2020-10-21 |
| — | UBS | Buy | — | — | Reiterated | 2020-10-14 |
| — | Barclays | Overweight | — | — | Reiterated | 2020-08-17 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2020-05-07 |
| — | UBS | Buy | — | — | Reiterated | 2020-05-07 |
INMD earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-10 | 0.42 | 0.46 | $101.5M | $103.9M |
| 2026-05-06 | 0.30 | 0.25 | $79.8M | $82.0M |
| 2026-08-05 | 0.35 | 0.35 | $93.1M | $95.6M |
| 2026-11-11 | 0.32 | 0.00 | $91.6M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.